Fungal infections in solid-organ transplantation

Clinical Infectious Diseases

Volumn 16, Issue 5, 1993, Pages 677-688

  Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CILOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; SAPERCONAZOLE;

ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; HUMAN; IMMUNOTHERAPY; INCIDENCE; INFECTION RISK; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

HEART TRANSPLANTATION; HEART-LUNG TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MYCOSES; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; RISK FACTORS;

EID: 0027222738     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clind/16.5.677     Document Type: Article

References (183)

1. Baumgartner WA, Reitz BA, Oyer PE, Stinson EB, Shumway NE, Cardiac homotransplantation. Curr Probl Surg 1979;16(9):1-61.
2. Dummer JS, Bahnson HT, Griffith BP, Hardesty RL, Thompson ME, Ho M, Infections in patients on cyclosporine and prednisone following cardiac transplantation. Transplant Proc 1983:15(suppls 1 and 2):2779-81.
3. Hoffiin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS, Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987;106:209-16.
4. Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M, Infections in heart-lung transplant recipients. Transplantation 1986;41:725-9.
5. Linder J, Infection as a complication of heart transplantation. Journal of Heart Transplantation 1988;7:390-4.
6. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS, Infectious complications in heart-lung transplant recipients. Am J Med 1985;79:412-22.
7. Dauber JH, Paradis IL, Dummer JS, Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990;11:291-308.
8. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988;67:132-43.
9. Paya CV, Hermans PE, Washington JA II, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989;64:555-64.
10. Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985;40:347-53.
11. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991;126:149-56.
12. Ho M, Infections in liver transplant recipients. In: Winter PM, Kang YG, ed. Hepatic transplantation. New York: Praeger, 1986;202-14.
13. Perkins JD, Frohnert PP, Service FJ, et al. Pancreas transplantation at Mayo. III, Multidisciplinary management. Mayo Clin Proc 1990;65:496-508.
14. Hesse UJ, Sutherland DER, Najarían JS, Simmons RL, Intra-abdominal infections in pancreas transplant recipients. Ann Surg 1986;203:153-62.
15. Dummer JS, Hardy A, Poorsattar A, Ho M, Early infections in kidney, heart and liver transplant recipients in cyclosporine. Transplantation 1983;36:259-67.
16. Hesse UJ, Fryd DS, Chatterjee SN, Simmons RL, Sutherland DER, Najarían JS, Pulmonary infections: the Minnesota randomized prospective trial of cyclosporine vs azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Arch Surg 1986;121:1056-60.
17. Kahana L, Narvarte J, Ackermann J, et al. OKT3 prophylaxis versus conventional drug therapy: single-center perspective part of a multi-center trial. Am J Kidney Dis 1989; 14(suppl 2):5-9.
18. Peterson PK, Balfour HH Jr. Marker SC, Fryd DS, Howard RJ, Simmons RL. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine(BaItimore) 1980:59:283-300.
19. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983;308:307-13.
20. Hamilton JR, Overall JC Jr, Glasgow LA, Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections. Infect Immun 1976;14:982-9.
21. Hamilton JR, Overall JC Jr, Glasgow LA, Synergistic infection with murine cytomegalovirus and Candida albicans in mice. J Infect Dis 1977;135:918-24.
22. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-54.
23. Gentry LO, Zeluff BJ, Diagnosis and treatment of infection in cardiac transplant patients. Surg Clin North Am 1986;66:459-65.
24. Dowling RD, Baladi N, Zenati M.etal. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg 1990;49:118-22.
25. Colonna JOII, Winston DJ, Brill JE, et al. Infectious complications in liver transplantation. Arch Surg 1988;123:360-4.
26. Fulginiti VA, Scribner R, Groth CG, Infections in recipients of liver homografts. N Engl J Med 1968;279:619-26.
27. Schröter GPJ, Hoelscher M, Putnam CW, Porter KA, Starzl TE, Fungus infections after liver transplantation. Ann Surg 1977; 186:115-22.
28. Rosen CB, Frohnert PP, Velosa JA, Engen DE, Sterioff S, Morbidity of pancreas transplantation during cadaveric renal transplantation. Transplantation 1991;51:123-7.
29. Cohen J, Hopkin J, Kurtz J, Infectious complications after renal transplantation. In: Morris PJ1 ed. Kidney transplantation. Principles and practice. 3rd ed. Philadelphia: WB Saunders, 1988:533-73.
30. Rifkind D, Marehioro TL, Schneck SA, Hill RB Jr. Systemic fungal infections complicating renal transplantation and immunosuppressive therapy: clinical, microbiologie, neurologic and pathologic features. Am J Med 1967;43:28-38.
31. Scroggs MW, Wolfe JA, Bollinger RR, Sanfilippo F, Cause of death in renal transplant recipients: a review of autopsy findings from 1966 through 1985. Arch Pathol Lab Med 1987; 111:983-7.
32. Morduchowicz G, Pitlik SD, Shapira Z, et al. Infections in renal transplant recipients in Israel. IsrJ Med Sci 1985;21:791-7.
33. Yoshino MT, Hillman BJ, Galgiani JN, Coccidioidomycosis in renal dialysis and transplant patients: radiologic findings in 30 patients. American Journal of Roentgenology 1987;149:989-92.
34. Hsu J, dayman JA, Geha AS, Survival of a recipient of renal transplantation after pulmonary phycomycosis. Ann Thorac Surg 1989;47:617-9.
35. Anandi V, John TJ, Walter A, et al. Cerebral phaeohyphomycosis caused by Chaetomium globosum in a renal transplant recipient. J Clin Microbiol 1989;27:2226-9.
36. Ramsey DE, Finch WT, Birtch AG, Urinary tract infections in kidney transplant recipients. Arch Surg 1979;1 14:1022-5.
37. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE, Infection in the renal transplant recipient. Am J Med 1981;70:405-11.
38. Ho M, Dummer JS, Peterson PK, Simmons RL, Infections in solid organ transplant recipients. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:2294-303.
39. Hooper DC, Pruitt AA, Rubin RH, Central nervous system infection in the chronically immunosuppressed. Medicine (Baltimore) 1982;61:166-88.
40. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS, Aspergillosis in 25 renal transplant patients: epidemiology. clinical presentation, diagnosis, and management. Ann Surg 1983;198:622-9.
41. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983;148:230-8.
42. Meunier F, Fungal infections in the compromised host. In: Rubin RH, Young LS, ed. Clinical approach to infection in the compromised host. 2nd ed. New York: Plenum, 1988:193-216.
43. Bodey GP, Vartivarian S, Aspergillosis. Eur J Clin Microbiol Infect Dis 1989;8:413-37.
44. Arnow PM, Andersen RL, Mainous PD, Smith EJ, Pulmonary aspergillosis during hospital renovation. Am Rev Respir Dis 1978; 118:49-53.
45. Kyriakides GK, Zinneman HH, Hall WH, et al. Immunologic monitoring and aspergillosis in renal transplant patients. Am J Surg 1976;131:246-52.
46. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW, Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982;116:430-7.
47. KJiardori N, Host-parasite interaction in fungal infections. EurJ Clin Microbiol Infect Dis 1989;8:331-51.
48. Meunier F, Candidiasis. Eur J Clin Microbiol Infect Dis 1989;8:438-47.
49. Gold JWM, Infectious complications of AIDS, In: Staquet M, Hemmer R, Baert A, eds. Clinical aspects of AIDS and AIDS-related complex. New York: Oxford University Press, 1986:93-100.
50. Potter van Loon BJ, Lichtendahl AT, Muider SS, Van Houten H, Gooszen HG, Van den Broek PJ, Microbial contamination of donor duodenum in whole-pancreas transplantation. Diabetes 1989; 38(suppl 1):242-3.
51. Warren RE, Newsome SWB, Bacterial, fungal, and protozoal infections in immunosuppressed patients. In: Calne RY, ed. Transplantation immunology. New York: Oxford University Press, 1984:518-66.
52. Groth CG, Lundgren G, Gunnarsson R, Arner P, Berg B, Östman J, Segmental pancreatic transplantation with duct ligation or drainage to a jejunal Roux-en-Y loop in nonuremic diabetic patients. Diabetes 1980;29(suppl 1):3-9.
53. Sutherland DER, Goetz FC, Najarian JS, Intraperitoneal transplantation of immediately vascularized segmental pancreatic grafts without duct ligation. Transplantation 1979;28:485-91.
54. Raith L, Csato M, Dobozy A, Decreased Candida albicans killing activity of granulocytes from patients with diabetes mellitus. Mykosen 1983;26:557-64.
55. Stone HH, Geheber CE, Kolb LD, Kitchens WR, Alimentary tract colonization by Candida albicans. J Surg Res 1973;14:273-6.
56. Stone HH, Kolb LD, Currie CA, Geheber CE, Cuzzell JZ, Candida sepsis: pathogenesis and principles of treatment. Ann Surg 1974;179:697-711.
57. Inoue S, Wirman JA, Alexander JW, Trocki O, Cardell RR, Candida albicans translocation across the gut mucosa following burn injury. JSurgRes 1988;44:479-92.
58. Katz S, Merkel GJ, Folkening WJ, Rosenthal RS, Grosfeld JL, Impaired clearance and organ localization of Candida albicans in obstructive jaundice. J PediatrSurg 1991;26:904-7.
59. Wiesner RH, Hermans PE, Rakela J, et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988;45:570-4.
60. Eppes SC, Troutman JL, Gutman LT, Outcome of treatment ofcandi-demia in children whose central catheters were removed or retained. PediatrInfect Dis J 1989;8:99-104.
61. Leibovitz E, Iuster-Reicher A, Amitai M, Mogilner B, Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992;14:485-91.
62. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-asso-ciated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
63. Rantala A, Niinikoski J, Lehtonen O-P. Yeasts in blood cultures: impact of early therapy. Scand J Infect Dis 1989;21:557-61.
64. Komshian SV, Uwaydah AK, Sobel JD, Crane LR, Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11:379-90.
65. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
66. Horn R, Wong B, Kiehn TE, Armstrong D, Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-55.
67. Powderly WG, Kobayashi GS, Herzig GP, Medoff G, Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
68. Bryce EA, Roberts FJ, Sekhon AS, Coldman AJ, Yeast in blood cultures: evaluation of factors influencing outcome. Diagn Microbiol Infect Dis 1992;15:233-7.
69. Meunier F, Aoun M, Bitar N, Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(suppl 1):S120-5.
70. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP, Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733-8.
71. Paulin T, Ringdén O, Nilsson B, Lönnqvist B, Gahrton G, Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 1987;43:393-8.
72. Meyers JD, Atkinson K, Infection in bone marrow transplantation. Clinicsin Haematology 1983;12:791-811.
73. Meyers JD, Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17(suppl 6):10-3.
74. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine and cadaveric renal transplantation: analysis at three years. N Engl J Med 1986;314:1219-25.
75. Busuttil RW, Goldstein LI, Danovitch GM, Ament ME, Memsic LDF, Livertransplantation today. Ann Intern Med 1986:104:377-89.
76. Kim JH, Perfect JR, Infection and cyclosporine. Rev Infect Dis 1989;11:677-90.
77. Barnhart GR, Hastillo A, Goldman MH, et al. A prospective randomized trial of pretransfusion/azathioprine/prednisone versus cyclo-sporine/prednisone immunosuppression in cardiac transplant recipients: preliminary results. Circulation 1985;72(suppl II): 227-30.
78. Graham-Pole J, Camitta B, Casper J, et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 1988;3:559-66.
79. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
80. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
81. Crawford SW, Hackman RC, Clark JG, Biopsy diagnosis and clinical outcome of persistent focal pulmonary lesions after marrow transplantation. Transplantation 1989;48:266-71.
82. Ness MJ, Vaughan WP, Woods GL, Candida antigen latex test for detection of invasive candidiasis in immunocompromised patients. J Infect Dis 1989;159:495-502.
83. Piens M-A, Guyotat D, Archimbaud E, et al. Evaluation of a Candida antigen detection test (Cand-Tec1) in the diagnosis of deep candidiasis in neutropenic patients. European Journal of Cancer and Clinical Oncology 1988;24:1655-9.
84. Kealey GP, Heinle JA, Lewis RW II, Pfaller MA, Rosenquist MD, Value of the Candida antigen assay in diagnosis of systemic candidiasis in burn patients. J Trauma 1992;32:285-8.
85. Tollemar J, Holmberg K, Ringdén O, Lönnqvist B, Surveillance tests for the diagnosis of invasive fungal infections in bone marrow transplant recipients. Scand J Infect Dis 1989;21:205-12.
86. Tollemar J, Ericzon B-G, Holmberg K, Andersson J, The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc 1990;22:242-4.
87. Johnson TM, Kurup VP, Resnick A, Ash RC, Fink JN, Kalbfleisch J, Detection of circulating Aspergillus fumigatus antigen in bone marrow transplant patients. J Lab Clin Med 1989; 114:700-7.
88. Rogers TR, Haynes KA, Barnes RA, Value of antigen detection in predicting invasive puimonary aspergillosis. Lancet 1990; 336:1210-3.
89. Haynes KA, Latge JP, Rogers TR, Detection of Aspergillus antigens associated with invasive infection. J Clin Microbiol 1990;28:2040-4.
90. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R, Predictive value of surveillance cultures for systemic infection due to Candida species. EurJ Clin Microbiol 1987;6:628-33.
91. Kaplan AH, Poza-Juncal F., Shapiro R, Stapleton JT, Cure of mucormycosis in a renal transplant patient receiving cyclosporin with maintenance of immunosuppression. Am J Nephrol 1988;8:139-42.
92. Walsh TJ, Pizzo A, Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988;7:460-75.
93. Graybill JR, New antifungal agents. Eur J Clin Microbiol Infect Dis 1989;8:402-12.
94. Denning DW, Stevens DA, Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Rev Infect Dis 1990;12:1147-201.
95. Meyer RD, Current role of therapy with amphotericin B, Clin Infect Dis 1992; 14(suppl 1):S154-60.
96. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA, Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-81.
97. Feely J, Heidemann H, Gerkins J, Roberts LJII, Branch RA, Sodium depletion enhances nephrotoxicity of amphotericin B [letter]. Lancet 1981;1:1422-3.
98. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED, Acute renal toxicity with combined use of amphotericin B and cy-closporine after marrow transplantation. Transplantation 1983; 35:211-5.
99. Gerson B, Cyclosporine controversies. Clin Lab Med 1987;7:669-86.
100. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;151:704-10.
101. Ralph ED, Khazindar AM, Barber KR, Grant CWM, Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxy-cholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother 1991; 35:188-91.
102. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP, Comparison of the in vitro antifungal activity of free and liposomc-cn-capsulated amphotericin B, Eur J Clin Microbiol Infect Dis 1991;10:665-8.
103. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. I reatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987;5:310-7.
104. Weber RS, Lopez-Berestein G, Treatment of invasive aspergillus si-nuss with liposomal-amphotericin B, Laryngoscope 1987;97:937-41.
105. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B, Arch Intern Med 1989;149:2533-6.
106. Patterson TF, Andriole VT, The role of liposomal amphotericin B in the treatment of systemic fungal infections. European Journal of Cancerand Clinical Oncology 1989;25(suppl 2):863-8.
107. Sculier JP, Bron D, Coune A, Meunier F, Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis 1989;8:903-7.
108. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
109. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(suppl B):83-91.
110. Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH, Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991;28(suppl B):93-104.
111. Coker RJ, Murphy SM, Harris JRW, Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother 1991;28(suppl B): 105-9.
112. Katz NM, Pierce PF, Anzeck RA, et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. Journal of Heart Transplantation 1990;9:14-7.
113. Tollemar J, Duraj F, Ericzon BG, Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses 1990;33:251-2.
114. Ralph ED, Barber KR, Grant CWM, Liposomal amphotericin B: an effective, nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans. Am J Nephrol 1991; 11:118-22.
115. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31.
116. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.
117. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with keto-conazole: results of a prospective randomized clinical trial. Ann Intern Med 1985;103:861-72.
118. Duarte PA, Chow GC, Simmons F Ruskin J, Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med 1984; 144:1069-70.
119. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG, Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86:503-13.
120. Janssen PAJ, Symoens JE, Hepatic reactions during ketoconazole treatment. Am J Med 1983;74(suppl B):80-5.
121. Ferguson RM, Sutherland DER, Simmons RL, Najarían JS, Ketoconazole, cyclosporin metabolism, and renal transplantation [letter], Uncet 1982;2:882-3.
122. Dieperink H, Maller J, Ketoconazole and cyclosporin [letter]. Lancet 1982;2:1217.
123. Smith J, Hows J, Donnelly P, Baughan A, Goldman J, Gordon-Smith EC. Interaction of cyclosporin A and ketoconazole. Exp Hematol 1983:1 (suppl 13):176-8.
124. White DJG, Blatchford NR, Cauwenbergh G, Cvclosporine and keto-conazole. Transplantation 1984;37:214-5
125. Grant SM, Clissold SP, Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
126. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ, Interaction of cyclosporin and itraconazole (letter). Lancet 1987;2:282.
127. Denning DW, Tucker RM, Hanson LU, Stevens DA, Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
128. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-14.
129. Washton H, Review of fluconazole: a new triazole aniifungal agent. Diagn Microbiol Infect Dis 1989:12(4)(suppl):229S-33S.
130. Andriole VT, Miniter P, George D, Kordick D, Patterson TF, Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992;14(suppl 1):S134-8.
131. Patterson TF, Miniter P, Andriole VT, Efficacy of fluconazole in experimental invasive aspergillosis. Reviews of Infectious Diseases 1990; 12(suppl 3):S281-5.
132. Patterson TF, George D, Miniter P, Andriole VT. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis 1991:164:575-80.
133. Dupont B, Drouhet E, Cryptococcal meningitis and fluconazole [letter], Ann Intern Med 1987:106:778.
134. Byme WR, Wajszczuk CP, Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B Ann Intern Med 1988;108:384-5.
135. Robinson PA, Knirsch AK, Joseph JA, Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990; 12(suppl 3):S349-63.
136. Larsen RA, Leal MAE, Chan LS, Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990; 113:183-7
137. Kujath P, Lerch K, Secondary mycosis in surgery: treatment with fluconazole. Infection 1989:17:111-7.
138. Saag MS, Powderly WG, Cloud GA. et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992:326:83-9.
139. Conti DJ, Tolkoft’-Rubin NE, Baker GP Jr. et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation 1989;48:692-5.
140. Houston JB, Humphrey MJ, Matthew DE, Tarbit MH, Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochem Pharmacol 1988;37:401-8.
141. Kruger HU, Schuler U, Zimmerman R, Ehninger Ci No severe drug interaction of fluconazole, a triazole antifungal agent, with cvclo-sporin. BoneMarrowTranspIant 1988;3(suppl 1):324-5.
142. Shaw JTB, Tarbit MH, Troke PF, Cytochrome P-450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles. In: Fromthing RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR ProusScience Publishers, 1987:125-39
143. Collignon P, Hurley B, Interaction between fluconazole and cvclo-sporin [letter]. Lancet 1989;2:867-8.
144. Sugar AM, Saunders C, Idelson BA, Bernard DB Interaction of fluconazole and cyclosporine. Ann Intern Med 1989:110:844.
145. Fisher MA, Shen S-H, Haddad J, Tarry WF, Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida g/abrara. and Candida krusei. Antimicrob Agents Chemother 1989;33:1443-6.
146. Akova M, Akalin HE, Uzun Ö, Giir D, Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole [letter], EurJ Clin Microbiol Infect Dis 1991;10:598-9.
147. Van Cutsem J, Van Gerven F, Janssen PAJ, Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Che-molher 1989;33:2063-8.
148. Denning DW, Hanson LH, Stevens DA, In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis 1990;9:693-7.
149. Meunier F, Lambert C, Van der Auwera P, In-vitro activity ofcilofun-gin (LY121019) in comparison with amphotericin B. J Antimicrob Agents Chemother 1989;24:325-31.
150. Flesch IEA, Schwamberger G, Kaufmann SHE, Fungicidal activity of IFN-7-activatcd macrophages: extracellular killing of Cr yptococcus neoformans. J Immunol 1989;142:3219-24.
151. Kramer P, ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W, Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant patients. Lancet 1984; 1:989-90.
152. Metcalf D, Morstyn G, Colony-stimulating factors: general biology. In: De Vita JR, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:417-44.
153. Masaoka T, Motoyoshi K, Takaku F, et al. Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone MarrowTransplant 1988;3:121-7.
154. Kojima S, Matsuyama T, Miyazaki T, et al. Treatment of aplastic anemia with KRN860I (rhG-CSF). Rinsho Ketsueki 1990; 31:929-36.
155. Hospenthal DR, Rogers AL, Beneke ES, Effect of attachment of anti-candidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother 1989;33:16-8.
156. Milliken ST, Powles RL, Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990; 12(suppl 3):S374-9.
157. Winston DJ, Ho WG, Gale RP, Champlin RE, Prophylaxis of infection in bone marrow transplants. European Journal of Cancer and Clinical Oncology 1988;24(suppl 1):S15-23.
158. Walsh TR, Guttendorf J, Dummer S, et al. The value of protective isolation procedures in cardiac allograft recipients. Ann Thorac Surg 1989;47:539-45.
159. Van der Waaij D, Vossen JM, Hartgrink CA, Nieweg HO, Polyene antibiotics in the prevention of Candida albicans colonization in the digestive tract of patients with severely decreased resistance to infections. In: Van der Waaij D, Verhoef J, ed. New criteria for antimicrobial therapy: maintenance of digestive tract colonization resistance. Amsterdam: Excerpta Medica, 1979:135-44.
160. Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wier-nik PH. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981;304:1057-62.
161. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminarair flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
162. Bodey GP, Rosenbaum B, Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine (Baltimore) 1974;53:209-28.
163. Meunier F, Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987;9:408-16.
164. Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell JH, Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect 1984;5:83-91.
165. De Vries-Hospers HG, Mulder NH, Sleijfer DT, van Saene HKF, The effect of amphotericin B lozenges on the presence and number of (’andida cells in the oropharynx of neutropenic leukemia patients. Infection 1982;10:71-5.
166. Mora NP, Cofer JB, Solomon H, et al. Analysis of severe infections (INF) after 180 consecutive liver transplants: the impact of amphotericin B prophylaxis for reducing the incidence and severity of fungal infections. Transplant Proc 1991;23:1528-30.
167. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-9.
168. Meunier-Carpentier F, Chemoprophylaxis of fungal infections. Am J Med 1984;76:652-6.
169. Meunier-Carpentier F, Cruciani M, KJastersky J, Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. European Journal of Cancer and Clinical Oncology 1983;19:43-8.
170. Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG, Efficacy of ketoconazole versus nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984; 144:549-51.
171. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R, Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984;144:290-3.
172. Bodey GP, Samonis G, Rolston K, Prophylaxis of candidiasis in cancer patients. Semin Oncol 1990; 17(suppl 6):24-8.
173. Samonis G, Rolston K, Karl C, Miller P, Bodey GP, Prophylaxis of oropharyngeal candidiasis with fluconazole. Reviews of Infectious Diseases 1990;12(suppl 3):S369-73.
174. Sugar AM, Saunders C, Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:481-9.
175. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
176. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Sarai R, Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
177. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
178. Prentice AG, Bradford GR, Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 1989; 32(suppl 1):96-102.
179. Mühldorfer SM, König HJ, Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients. Mycoses 1990;33:291-5.
180. Meunier F, New methods for delivery of antifungal agents. Reviews of Infectious Diseases 1989;11(suppl 7):51605-12.
181. Schmitt HJ, Bernard EM, Hauser M, Armstrong D, Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32:1676-9.
182. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR, Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990;5:403-6.
183. Walsh TJ, Lee JW, Lecciones J, et al. SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob Agents Chemother 1990;34:1560-4.